Vérane Schwiertz

1.1k total citations
31 papers, 607 citations indexed

About

Vérane Schwiertz is a scholar working on Pediatrics, Perinatology and Child Health, Oncology and Geriatrics and Gerontology. According to data from OpenAlex, Vérane Schwiertz has authored 31 papers receiving a total of 607 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pediatrics, Perinatology and Child Health, 9 papers in Oncology and 8 papers in Geriatrics and Gerontology. Recurrent topics in Vérane Schwiertz's work include Pharmaceutical Practices and Patient Outcomes (8 papers), Pharmaceutical studies and practices (8 papers) and Patient Safety and Medication Errors (6 papers). Vérane Schwiertz is often cited by papers focused on Pharmaceutical Practices and Patient Outcomes (8 papers), Pharmaceutical studies and practices (8 papers) and Patient Safety and Medication Errors (6 papers). Vérane Schwiertz collaborates with scholars based in France, United States and Switzerland. Vérane Schwiertz's co-authors include Catherine Rioufol, Florence Ranchon, Nicolas Vantard, Gilles Salles, Gilles Freyer, Benoît You, Stéphanie Parat, Émilie Hénin, Claude Dussart and V. Trillet-Lenoir and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Vérane Schwiertz

30 papers receiving 592 citations

Peers

Vérane Schwiertz
Florence Ranchon France
Nicolas Vantard France
B. Gourieux France
Vicente Escudero‐Vilaplana Spain
Sylvia Bartel United States
Carole Chambers Canada
John Valgus United States
Raymond J. Muller United States
Mikaël Daouphars France
Scott W. Savage United States
Florence Ranchon France
Vérane Schwiertz
Citations per year, relative to Vérane Schwiertz Vérane Schwiertz (= 1×) peers Florence Ranchon

Countries citing papers authored by Vérane Schwiertz

Since Specialization
Citations

This map shows the geographic impact of Vérane Schwiertz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vérane Schwiertz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vérane Schwiertz more than expected).

Fields of papers citing papers by Vérane Schwiertz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vérane Schwiertz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vérane Schwiertz. The network helps show where Vérane Schwiertz may publish in the future.

Co-authorship network of co-authors of Vérane Schwiertz

This figure shows the co-authorship network connecting the top 25 collaborators of Vérane Schwiertz. A scholar is included among the top collaborators of Vérane Schwiertz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vérane Schwiertz. Vérane Schwiertz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Piffoux, Max, Alexandra Léary, Philippe Follana, et al.. (2025). Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial. Nature Communications. 16(1). 1821–1821. 1 indexed citations
2.
3.
Puszkiel, Alicja, Michel Tod, Sara Calattini, et al.. (2023). Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors. Cancer Chemotherapy and Pharmacology. 91(5). 361–373. 2 indexed citations
4.
Baudouin, Anne, et al.. (2021). Real-life drug–drug and herb–drug interactions in outpatients taking oral anticancer drugs: comparison with databases. Journal of Cancer Research and Clinical Oncology. 148(3). 707–718. 30 indexed citations
5.
Ranchon, Florence, Laure Huot, Isabelle Carpentier, et al.. (2020). Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients’ knowledge to manage adverse effects. PLoS ONE. 15(12). e0243309–e0243309. 4 indexed citations
6.
Paré, Maxime C., P Benoit, Vérane Schwiertz, et al.. (2019). What do adult outpatients included in clinical trials know about the investigational drugs being assessed: A cross-sectional study in France. PLoS ONE. 14(8). e0220383–e0220383. 2 indexed citations
7.
Saux, Olivia Le, Aurélie Bourmaud, Catherine Rioufol, et al.. (2018). Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients. Cancer Chemotherapy and Pharmacology. 82(2). 319–327. 15 indexed citations
8.
Fargier, Emilie, Nicolas Vantard, Florence Ranchon, et al.. (2017). Évolution du remboursement des anticancéreux inscrits sur la liste en sus : impact financier au sein d’un centre hospitalo-universitaire. Bulletin du Cancer. 104(6). 538–551. 2 indexed citations
9.
Fargier, Emilie, Florence Ranchon, Laure Huot, et al.. (2017). SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma. Annals of Hematology. 97(1). 123–131. 16 indexed citations
10.
Schwiertz, Vérane, Céline Alloux, Nicolas Vantard, et al.. (2016). SIMulation of Medication Error induced by Clinical Trial drug labeling: the SIMME-CT study. International Journal for Quality in Health Care. 28(3). 311–315. 7 indexed citations
11.
Ranchon, Florence, Nicolas Vantard, Vérane Schwiertz, et al.. (2016). Comparative toxicities of 3 platinum‐containing chemotherapy regimens in relapsed/refractory lymphoma patients. Hematological Oncology. 35(4). 584–590. 28 indexed citations
12.
Ranchon, Florence, Lila Gilis, Vérane Schwiertz, et al.. (2015). Cidofovir in the Treatment of BK Virus–Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 22(4). 723–730. 58 indexed citations
13.
Ranchon, Florence, Amélie Boespflug, Catherine Rioufol, et al.. (2015). New Treatments for Cutaneous Metastatic Melanoma: MAPK Pathway-Targeted and Immune Based Therapies. Anti-Cancer Agents in Medicinal Chemistry. 15(4). 461–467. 7 indexed citations
14.
Dupuis‐Girod, Sophie, Évelyne Decullier, Géraldine Samson, et al.. (2014). ELLIPSE Study. mAbs. 6(3). 793–798. 39 indexed citations
15.
Ranchon, Florence, Audrey Nosbaum, Benoît You, et al.. (2014). Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacology and Toxicology. 15(1). 1–1. 70 indexed citations
16.
Rioufol, Catherine, Florence Ranchon, Vérane Schwiertz, et al.. (2014). Administration of Anticancer Drugs: Exposure in Hospital Nurses. Clinical Therapeutics. 36(3). 401–407. 12 indexed citations
17.
Ranchon, Florence, Benoît You, Gilles Salles, et al.. (2013). Improving Cancer Patient Care with Combined Medication Error Reviews and Morbidity and Mortality Conferences. Chemotherapy. 59(5). 330–337. 8 indexed citations
18.
Ranchon, Florence, Benoît You, Gilles Salles, et al.. (2012). Predictors of prescription errors involving anticancer chemotherapy agents. European Journal of Cancer. 48(8). 1192–1199. 32 indexed citations
19.
Ranchon, Florence, Gilles Salles, Hans-Martin Späth, et al.. (2011). Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. BMC Cancer. 11(1). 478–478. 93 indexed citations
20.
Ranchon, Florence, Nicolas Vantard, Aurore Gouraud, et al.. (2011). Suspicion of Drug-Drug Interaction between High-Dose Methotrexate and Proton Pump Inhibitors: A Case Report – Should the Practice Be Changed?. Chemotherapy. 57(3). 225–229. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Florence Ranchon Breakdown of academic impact, for papers by Nicolas Vantard Breakdown of academic impact, for papers by B. Gourieux Breakdown of academic impact, for papers by Vicente Escudero‐Vilaplana Breakdown of academic impact, for papers by Sylvia Bartel Breakdown of academic impact, for papers by Carole Chambers Breakdown of academic impact, for papers by John Valgus Breakdown of academic impact, for papers by Raymond J. Muller Breakdown of academic impact, for papers by Mikaël Daouphars Breakdown of academic impact, for papers by Scott W. Savage
Rankless by CCL
2026